AbCellera Biologics Inc. (ABCL) News

AbCellera Biologics Inc. (ABCL): $7.90

-0.40 (-4.82%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ABCL to Watchlist
Sign Up

Industry: Biotech


Ranked

of 395

in industry

Filter ABCL News Items

ABCL News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ABCL News Highlights

  • ABCL's 30 day story count now stands at 14.
  • Over the past 28 days, the trend for ABCL's stories per day has been choppy and unclear. It has oscillated between 1 and 7.
  • DECK are the most mentioned tickers in articles about ABCL.

Latest ABCL News From Around the Web

Below are the latest news stories about AbCellera Biologics Inc that investors may wish to consider to help them evaluate ABCL as an investment opportunity.

AbCellera Biologics Inc. 2021 Q4 - Results - Earnings Call Presentation

The following slide deck was published by AbCellera Biologics Inc. in conjunction with their 2021 Q4 earnings call....

SA Transcripts on Seeking Alpha | February 24, 2022

AbCellera Biologics GAAP EPS of $0.19 beats by $0.01, revenue of $139.3M beats by $17.44M

AbCellera Biologics press release (ABCL): Q4 GAAP EPS of $0.19 beats by $0.01.Revenue of $139.3M beats by $17.44M.“In 2021 we made significant advancements in executing our…

Seeking Alpha | February 24, 2022

AbCellera Reports Full Year 2021 Business Results

VANCOUVER, British Columbia, February 24, 2022--AbCellera Reports Full Year 2021 Business Results

Yahoo | February 24, 2022

AbCellera Biologics Q4 2021 Earnings Preview

AbCellera Biologics (NASDAQ:ABCL) is scheduled to announce Q4 earnings results on Thursday, February 24th, after market close.The consensus EPS Estimate is $0.17 and the consensus…

Seeking Alpha | February 23, 2022

AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools

VANCOUVER, British Columbia, February 23, 2022--AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools

Yahoo | February 23, 2022

AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm

No summary available.

Seeking Alpha | February 11, 2022

AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19

VANCOUVER, British Columbia, February 11, 2022--AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild to Moderate COVID-19

Yahoo | February 11, 2022

AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022

VANCOUVER, British Columbia, February 11, 2022--AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022

Yahoo | February 11, 2022

Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments

VANCOUVER, British Columbia, February 11, 2022--Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Bebtelovimab to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments

Yahoo | February 11, 2022

AbCellera to Report Full Year 2021 Financial Results on February 24, 2022

VANCOUVER, British Columbia, January 27, 2022--AbCellera to Report Full Year 2021 Financial Results on February 24, 2022

Yahoo | January 27, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6982 seconds.